Dianthus Therapeutics Inc
dianthustx.comWhat Do They Do?
Develops antibody and fusion-protein drug candidates for people with severe autoimmune diseases.
10-K for FY2025, filed Mar 9, 2026
How Do They Make Money?
Tenacia pays an upfront fee, reimburses some development costs, may owe development milestone payments, and pays royalties on licensed-product sales in Greater China; a separate option could lead to another license payment.
10-K for FY2025, filed Mar 9, 2026
$2M
-
10-K for FY2025, filed Mar 9, 2026
$2M ↗
Who Are Their Customers?
Tenacia holds the Greater China license for claseprubart and can research, develop, manufacture and commercialize it; Dianthus also entered an exclusive license agreement with Leads for DNTH212.
10-K for FY2025, filed Mar 9, 2026On June 10, 2022, in connection with Zenas’s exercise of the option, we entered into a license agreement with Zenas (the “Zenas License…View ↗
On October 21, 2024, Zenas assigned the Zenas License Agreement to its affiliated entity, Zenas BioPharma (HK) Limited (“Zenas HK”). After…View ↗
As consideration for the license, which replaced the consideration of the Zenas License Agreement with respect to the first antibody…View ↗
On October 16, 2025, we entered into an exclusive license agreement with Nanjing Leads Biolabs Co., Ltd. (“Leads”) for DNTH212, a first and…View ↗
Do Revenues Turn Into Profits?
No. It lost $162.3M in FY2025.
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 4, 2026
−$50.2MView ↗
- ▲ +59% (Loss)
- vs −$31.6M in Q2 FY2025
Therapeutic focus
Moved from stem-cell transplant conditioning and mobilization candidates to antibody and fusion-protein drug candidates for severe autoimmune diseases.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 9, 2026
Who Do They Compete With?
Competes with AstraZeneca, argenx, UCB, Johnson and Johnson, Amgen, Pfizer, CSL Behring, Grifols Therapeutics, Sanofi, and Takeda
10-K for FY2025, filed Mar 9, 2026There is significant competition in gMG. AstraZeneca’s Soliris® and Ultomiris®, both I.V. C5 inhibitors, argenx’s Vyvgart® (efgartigimod)…View ↗
Loading...
